Fabre-Kramer Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5847 San Felipe St Ste 2000, Houston, Te...Phone Number
(713) 975-6900Website
www.fabrekramer.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Fabre-Kramer Pharmaceuticals
Fabre-Kramer Pharmaceuticals, Inc. specializes in the identification, development, and commercialization of psychotropic drugs aimed at treating psychiatric and neurologic disorders. The company is currently focused on the commercial launch of its lead product, Gepirone Hydrochloride. Their intended clients include healthcare providers and patients in need of psychiatric and neurologic treatments. Fabre-Kramer is recognized as a leader in the pharmaceutical industry for its innovative approaches to mental health care.Explore more
Fabre-Kramer Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Fabre-Kramer Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Fabre-Kramer Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Fabre-Kramer Pharmaceuticals has new funding data
Click to see if Fabre-Kramer Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Fabre-Kramer Pharmaceuticals
Product Launch: Get notified when Fabre-Kramer Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Fabre-Kramer Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Fabre-Kramer Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Fabre-Kramer Pharmaceuticals recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Fabre-Kramer Pharmaceuticals
Compare insights from companies similar to Fabre-Kramer Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Fabre-Kramer Pharmaceutic...
<$5M
1-10
Private
-
1992
SR
Samir RosenthalVice President, Sales & Marketing
Company Profile Activity
Activity Insights
Fabre-Kramer Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Fabre-Kramer Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Fabre-Kramer Pharmaceuticals.
Fabre-Kramer Pharmaceuticals Tech Stack
A closer look at the technologies used by Fabre-Kramer Pharmaceuticals
See more technologies
Fabre-Kramer Pharmaceuticals News & Media
Fabre-Kramer Submits NDA Amendment for Exxua ™ for Treatment of Major Depressive Disorder
HOUSTON, Jan. 4, 2023 /PRNewswire/— Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug Administration (FDA) for its novel mechanism antidepressant... (Source: Drugs.com - New Drug Applications)Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of PDUFA Regulatory Action Date
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date of June 23, 2023. HOUSTON, Jan. 24, 2023 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals, a leading developer of novel small molecule...Fabre-Kramer Submits NDA Amendment for EXXUA™ for Treatment of Major Depressive Disorder
New Class of Antidepressant's Novel Mechanism Uniquely and Directly Addresses Important Unmet Needs HOUSTON, Jan. 4, 2023 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug...FABRE-KRAMER PARTNERS WITH MISSION PHARMACAL FOR FUTURE COMMERCIAL MANUFACTURE OF NOVEL MECHANISM ANTIDEPRESSANT TRAVIVO™ (GEPIRONE HCL) TABLETS
HOUSTON, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) of Houston, TX, and Mission Pharmacal Company (Mission) of San Antonio, TX, announced today that they have signed agreements providing for Mission to complete the technology transfer to develop and manufacture the registration batches of Fabre-Kramer’s novel antidepressant, Travivo (gepirone HCl) Extended Release Tablets. Data from these batches will be used to support the submission of the NDA Amendment
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Fabre-Kramer Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Fabre-Kramer Pharmaceuticals, Inc. specializes in the identification, development, and commercialization of psychotropic drugs aimed at treating psychiatric and neurologic disorders. The company is currently focused on the commercial launch of its lead product, Gepirone Hydrochloride. Their intended clients include healthcare providers and patients... Read More
